Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welllll loooks like I was right on my price target. I guess you know who is more credible on price predictions now when it comes to this board.
But I was wrong here as well.
The court case did give USRM a PR rep and now it appears this company is in smoldering ashes from the FDA and all the claims/suits.
But now... no one has said a thing about the position this company is in. Greedy hands don't often speak of their moves... so I guess I'll introduce the elephant in the room.
USRM has no audited reports, so what is Miguel's word really worth? is he signing the truth on his SEC reports? is it just him compiling these reports on his own, from a remote login? could be.. but either way...
USRM has successfully given the FDA case law to now pounce and prohibit physicians in the U.S. from using the adipose stem procedure. Out of all the cases showing the procedure does work for serious conditions which no pharma company can compare.. let's just say the FDA screwed up a lot of lives on this one. In my neighborhood, a child was awaiting a stem cell injection into her pancreas, as the latest evidence has shown this has been curing diabetes. But let's just worry about the lady that went blind after the procedure when she was going blind (did that make sense?). Forget about the ones that can be saved which outnumber 1000 to 1?
So now USRM is positioned as far as we can see (per management)... that they may be the most qualified and most readily positioned entity to submit a stem cell biologic NDA.
SO to USRM, the move is NAD+ injections or first stem cell approved biologic drug for maybe.. myocarditis (the disease resulting from the Covid-19 vax), or how about another heart condition?
Banks won't touch this stock, so I'm in 10-fold at .008.
You can say BK all day.. but realistically why didn't they do that years ago? you have to give these shysters some credit, the more lucrative scam is to keep this dog n pony show going.
WARNING DO NOT TRADE USRM.
This stock does not file with the SEC since 2019
USRM court case is a scam to buy time.
This company can’t sell anything by being in court. But that’s a lie. Plenty of companies are sued everyday but don’t stop selling and gaining revenue.
USRM awaits an appeal opinion with no where to go.
Is this company really being slowed down by the appeal or is the appeal an excuse for the fact this company will never grow.
USRM price dumping to at least .029 is looking obvious.
Is this the final dump to .019?
USRM on track for downfall to .03 and below.
USRM teaches investors appellate procedure
USRM support gone at mid-.04..
Heading south below .04 ??
Investing in USRM will have you looking at court dockets.
USRM fails to overcome .05 and continues down trend.
This company lacks PR and will continue to see reduced volume traded as it heads to .03.
Maybe this is because after a decade of research in stem cells, they decided to sell ozone therapy?
USRM hasn’t done any ozone therapy research have they?
A negative court court ruling should get this PPS down to sub penny...
USRM heading down sub .045 confirmed pps target.
Dumps are in play and this stock has no where to go but down. USRM will be cutting up pennies soon, as their shares hit fractional amounts.
USRM pps of .018 in play.
USRM is going Sub .045... time for shorts to get in.
An unfavorable ruling may well destroy this pps to .001 company!
Let’s go BK!
USRM shorts hitting big gains!!
Price below .06 and .05 confirmed!
.03 OTW!
USRM .40 price target Yahoo = computer glitch
Something must be in error here as this price target has not been updated. .40 is a kookooo expectation for this stock.
USRM expected to be at a solid .045 by mid March.
Then long term outlook to .012 by June this year.
USRM shares are overvalued. Sad to say at .06
Do not invest in a company that has no filed financials. This company has zero momentum in stem cell products compared to the clinics across the world already using this practice...
USRM is behind the curve and has no way to catch up. Every step they try to take forward will bring another lawsuit on their desk from bad dealings.
USRM going sub .05. barcharts say no buy.
USRM Isn’t making enough money through diet counseling and now the pavement is hitting and sub .05 is in play.... down to .042 and then .03 to then 019.
Dilution dilution... cause there is no solution.... when you have a team that can’t sell what’s in their name.
USRM offers Ozone Therapy.. why bother with them?
This company just finds whatever they can to throw into a downward spiral of losses.
U. S. Stem Cell embarrasses all its stakeholders with non stem cell products that never turn a profit. Don’t invest in this no-plan company.
USRM dumps like a log ?? ?? as it’s meant to do.
.058 to sub .045 in next days expected down to BK after hitting .019
USRM target of .019 after release of court decision.
Once the court chatter is gone... they have effectively Zero PR and price is expected to decline while other stem cell clinics take advantage of the new ruling, which that they are already operating in.
USRMs court case will promote the competition clinics more so than USRM due the company’s horrible track record of law suits.
Let the more diligent practitioners use stem cells for patients in a non-public entity.
.019 is still in play.
USRM .4 target price on yahoo is a lie
There’s no merit for this hypothetical target, that has been the same for years.
USRM has no long term growth.
This stock is a loser. You have Knutson is over here with +30M shares like oh I dun Effd up. Save your retirement funds people and run for the hills away from this stock.
Don’t be Greg. Just say and repeat. Then put your diamond hands elsewhere.
Started in 99 they did and have done both. All they’ve done is research. But can’t make a dime in profit with any of it. Please don’t bother with them.
USRM begins down trend on week.
As expected the gains were unsustainable and any buyers of this share at .05 are now loosing hefty %%.
Sub .04 in play... but to continue to .019
USRM a 100% sell according to false hopes.
USRM the biggest let down of a company is no breaching sub .05 and into .04 territory.
Lack of any movement as usual with this company will put it back on track to sub .019.
Who’s paying to store the cryogenic cells that are banked? Certainly they’re not in dewars in a Regis office?
Don’t blind yourself buying into USRM.
What do you think their revenue is for 2019?
Looking at he facts..
They’ve been doing research since 1999 you know... so 2 decades later...
what do you think their revenue is based on 2018 numbers? And bottom line is?
USRM can’t even provide the revenue for 2019. How much is it?
Respond here what you think it is if you even care?
USRM declines in price eyeing sub .04
This stock has no rebound in play so maybe a flat at sub penny is realistic to think. Don’t fool yourself with this company. It has no SEC filings and I had never made a positive net income.
USRM is worse than a failing vitamin supplement store. But a Nutri-Shop is at least FDA compliant.
USRM can’t make any drugs themselves or devices so they load up on wacky products and lack advertising that of which is only put out towards a limited market.
They’re stuck in and out of court and haven’t made a dent in the billion dollar stem cell market that’s just passing them by.
There’s better companies out there especially during the COVID pandemic. As a medical specialties company you would expect some treatment options using stem cells... but no. Even after physicians in India clinically tested curing lung conditions due to COVID infection,... USRM still cannot figure out how to make any effort into this market space, even with the amount of research they have done.
Save your hard earned money. This company funnels your cash into a Regus Virtual office to 4 people and their attorney’s.
USRM is a failing tickler to your portfolio
Don’t let any recent orders let you think there’s value here. The floor on .06 is tissue paper thin. Breaching that to .03 is the obvious chart setup rn. Don’t be blind unless it’s not your fault.
There’s no validating this current price.
No body has the answer in this case and the company is flat.
Did your financial advisor recommend this stock? No... cause you’re probably throwing your money away.
This company is the biggest audit red flag for the SEC.
Doing some illegal stuff in front of the FDA and then expecting to be able to build a company is not how fizer started.
USRM provides Diet Counseling similar to Herbalife
Does that mean they have certified nutritionalists? Or its a bunch of people who studied pubmed?
How is this stem cells again? Oh right... they can’t make money in that war. But others are. We all know others are.
USRM gains unsustainable.
There is no momentum other than some hush lips on a court case appeal decision.
False hope assumes this decision is the light at the end of the tunnel. But court cases don’t = revenue. So another going concern in the financial statements? If they find a CPA pro-Bono? does Tomas know how the revenue cycle works in a for profit company?
Short term buyers expecting to vacate. Especially after the judgement is released (in favor or against)
Sub .019 still in play.
USRM .054 wall to dump back to sub .03.
Fundamentally flawed USRM has no direction in the arena of stem cells other than they may have done some research back in the day. Maybe the initials should stand for U.S. Regenerative Medicine. They’ve lost their grip on the stem cell market, so they’re throwing in procedures like laser therapy and NAD injections which are not for low, mid or large cap companies.. cause there’s no large market. No plan exists to turn this company a profit and the accountants just keep slapping on that ‘going concern’ in every audit.
This is just the blind leading the blind.
Sub.019 after the .04 wall is hit. No escapes the wall, not even comella.
Light years after a 5 million IPO with no proprietary or patents or software but training at $500 a pop. And performing a procedure that’s being done by many physicians in their own practices... USRM fits in an NPO category since they’ve seen to contributed research but lack the expertise to capitalize to anything profitable.
USRM going to sub .019. There’s no young blood in this company.
USRM has relied on their research but has failed to adapt to the market, which is why they started selling training and ‘regenerative products’. The procedures they train... well there’s a lot of training companies doing the same. Additionally there’s even evidence showing that the rejection rate of donor cells is conflicted and actually low. In fact in certain scenarios an Autogolos procedure is less beneficial.
With 500k in capital I could bring a functioning product for allogeneic cells making the same day procedure in adequate, and no training required on extraction but only on administration of the cells.
Stem cells will continue to play a role in medicine in an decentralized manner, where clinicians can perform the procedure similar to other procedures. THE only thing USRM has is the research they’ve done. But allogeniec cells are proving to be beneficial.
My theoretical company will be a provider of allo-MSC cells and thus have something tangible to distribute. But to get in the game of being a clinic to provide a more risky procedure of auto-MSC administration could be where USRM is headed along with an influx of physicians performing the procedure, so there is no market advantage USRM has... other than their claim to research. But they can’t monetize the research, which is why other clinicians are now doing the procedure and nobody has to pay 2 cents to USRM, even though USRM has the longest record of dealing in this market. USRM has no market advantage with their procedures, and no tangible product to distribute. Regenerative products may be effective to an extent but without being covered by insurance who will really buy these products? And let’s say you do all the USRM products and pay 100k, are you going to walk away with new hair? Maybe you will but why not go to another regenerative medicine clinic?
USRM needs to work a tangible device, product or service into medical protocols in order to gain market advantage.. for example a device specifically made to fit in a cast, like a valve,
and after each cast is applied it allows you to inject cells through the cast... this patented pending device is then worked into the procedure of every cast and is insurable cause it’s the only one approved. The founder of USRM who is 97 is known for making medical devices and could fit this in. But yes more clinical trials will remain.
But you get the idea of where this market is, and how to capitalize? The myocatheter was a great idea and well if something like that doesn’t get in play... these regenerative medicine products are just anything mom and pop could be selling on the Vegas strip for hungover tourists... (btw there is a NAD injection clinic in one of the lobbies as we speak, and oxygen bars are not new)